CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.

This is a randomized phase II study, open-label and multicentric. After initial intervention (debulking surgery or diagnostic surgery) patient will randomized in the study according to Completeness of cytoreduction (CC) score (CC0 or CC>1).

Inclusion Criteria:

• Histologically confirmed advanced (FIGO stage III or IV) invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer. Pleural cytology has to be performed in patients with pleural effusion.
• Initial intervention : debulking surgery or diagnostic surgery in the 3 weeks before inclusion
• Age ≥18 and < 75 years old.
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 before surgery (ECOG ≤ 1 and Lee score < 6 in patients > 70 years old).
• Adequate blood count (test realized in the past 14 days before inclusion) : neutrophils > 1500/mm3, platelets > 150 000/mm3.
• Creatinine clearance MDRD ≥ 60 mL/min
• Registration in a national health care system (CMU included).
• Signed and dated informed consent.

Exclusion Criteria:

• FIGO stage IV extra-abdominal disease, with the exception of lymph nodes and pleural invasion.
• Patient having received previous chemotherapy for ovarian cancer.
• Left ventricular ejection fraction < 50% before chemotherapy initiation
• Other invasive cancer in the past 5 years (baso- and spinocellular cutaneous carcinoma with complete resection are accepted)
• Concomitant administration of prophylactic phenytoin or live attenuated viral vaccines such as yellow fever vaccine,
• Patients with known hypersensitivity to any component of study drug
• Patients without motivation or capacity to respect study requirements and constraints
• Pregnancy or breast feeding women